BillionToOne (BLLN)

In women’s health, the company offers the UNITY portfolio of prenatal tests. UNITY is used to assess fetal risk for certain inherited and chromosomal conditions from a maternal blood sample, including applications where testing can be performed without requiring a paternal sample. The approach is intended to give clinicians and expectant parents more actionable information during pregnancy while relying on a non-invasive sample type.

BillionToOne also applies its platform to cancer diagnostics through the Northstar product line. Northstar Select is a liquid biopsy test used to help identify therapy-relevant genomic alterations in patients with advanced cancer. Northstar Response is a tissue-free, pan-cancer blood test that tracks methylation signals associated with cancer, providing information that may help clinicians monitor changes in disease burden and response to treatment over time.

The company operates in a competitive diagnostics market shaped by advances in next-generation sequencing, liquid biopsy, precision oncology, and reproductive health testing. Its differentiation rests on the sensitivity of its molecular counting platform and the breadth of use cases it supports across both prenatal genetics and cancer care. For investors, BillionToOne represents exposure to the growth of specialised diagnostic testing, where adoption depends on clinical utility, physician uptake, reimbursement, and continued evidence generation.